about
Extracellular Vesicles: Role in Inflammatory Responses and Potential Uses in Vaccination in Cancer and Infectious DiseasesHealth and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programmeMonoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activityRespiratory virus infection and risk of invasive meningococcal disease in central Ontario, CanadaVaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST database.The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant.Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease.Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.The impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission.Identification of Outer Membrane Vesicles Derived from Orientia tsutsugamushi.International circumpolar surveillance interlaboratory quality control program for serotyping Haemophilus influenzae and serogrouping Neisseria meningitidis, 2005 to 2009A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp.Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles.Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European CountriesThe new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria.Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccinesLipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Bacterial outer membrane vesicles in disease and preventive medicine.Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.Regulation of capsule in Neisseria meningitidis.The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.Phase variation of Opa proteins of Neisseria meningitidis and the effects of bacterial transformation.Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.Population coverage analysis of T-Cell epitopes of Neisseria meningitidis serogroup B from Iron acquisition proteins for vaccine design.Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989-2010).A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.
P2860
Q26783960-2D7BC70E-B4AC-4BDE-8475-37607A88AEEDQ28391723-0A110EEE-EC91-40EB-92E3-6993B6EF1F7CQ28730934-879B87E0-2F5E-4ABC-9B97-FF78354D8E3AQ33754620-AE0E1CCA-6F5A-4F94-8014-DCE5DB7173BAQ34113328-5203F08A-0DCB-4CAA-A523-641665B458F9Q34270429-94CF9B1D-D4E2-4474-B050-F37E9C255B14Q34428829-50CFAEE1-D8EF-4859-91A8-5E33B1CE5874Q34500581-9072B9C5-EF9E-4278-B2FA-1B50037017EAQ34516060-2D594F6F-4DDC-4D60-8AE6-CDBEEEC4B4DCQ35191828-11ACEA7F-CAC9-4AC6-B415-5D8F3B2C9AEBQ35191862-02C7E3C7-FA91-4DD6-BB31-8056374CCB02Q35453441-1E25016E-7CE5-4C7D-9141-4313943F4EE3Q35665404-BDDA5607-CEF5-4A6A-B91F-E722B8A19189Q35724206-A43A4144-62FF-4C0C-907C-6BCA0FBEFA31Q35778551-A6D31357-4C95-4C77-BE5C-B0A5C8701C2EQ35807124-A47F41DB-B170-4068-BA3D-CA490E3C710EQ35857593-55FB2F33-E773-43C5-A58E-8FD24F606B57Q35887617-D13A4FDE-0680-4B43-A577-17A6E36C032FQ35922195-D89F0BAF-1A03-4244-BB2D-5F71E03D6C6DQ35947795-FE786F40-A652-4F3A-A071-6E463853804AQ35989852-EDBD8D93-5596-4BD5-84CE-4EAAEC5D05B8Q36016022-87309070-5292-4F57-A784-2ABE0D671274Q36362282-AE9AC95A-2177-4FFF-B405-753DA00114FFQ36970778-080D9C40-7710-42C3-BF5C-3DFD51244E60Q37124721-ABAF8AB4-4DCF-464F-8FAC-46FA7AA4C949Q37309237-A8076B93-967D-42D1-9B04-C46D777268A4Q37514748-5A516A42-191A-4256-9481-6FF8DF436255Q37820396-42F5677D-A05A-4FF6-9C33-407F4253C478Q37857249-0AB77591-35CF-434F-BF81-7F8478C3328FQ38132262-64C9550E-6486-46B1-9475-4428EEFCAF9CQ38176077-468EB7D3-C43E-44A8-B62F-208F95B88424Q38531723-93009B73-B751-4FA7-A4C9-527C4F8C3517Q38599522-BC43CCDA-AB02-495B-A363-11B75F98BFB0Q38775024-1DD22CDA-3F43-474A-A4D4-AE8B8F82CFE4Q39418716-7B951708-1056-4A46-8F60-E9E7E6B5522DQ40168476-A6FA49D3-B16E-4D4D-915C-2AFC104890CCQ40179042-0D1AB8AB-BBAF-4799-B92D-8D2D2C357BF7Q42776796-8A91E0E0-AC0D-48D8-B62E-D539BA69A6BBQ44536708-EF619DAA-2EC5-4994-8469-F097DE097430Q46272338-8C4612CB-03C4-4D17-B8D0-DD26AA2B71D0
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serogroup B meningococcal vaccines-an unfinished story.
@en
Serogroup B meningococcal vaccines-an unfinished story.
@nl
type
label
Serogroup B meningococcal vaccines-an unfinished story.
@en
Serogroup B meningococcal vaccines-an unfinished story.
@nl
prefLabel
Serogroup B meningococcal vaccines-an unfinished story.
@en
Serogroup B meningococcal vaccines-an unfinished story.
@nl
P1476
Serogroup B meningococcal vaccines-an unfinished story.
@en
P2093
Andrew J Pollard
P304
P356
10.1016/S1473-3099(09)70324-X
P577
2010-02-01T00:00:00Z